Last updated: February 20, 2026
European Patent EP2176234, titled "Cytokine Receptor Antagonists," covers novel compounds and methods related to cytokine receptor antagonists used in inflammatory and immune-related conditions. The patent claims cover specific chemical structures, their binding methods, and therapeutic applications.
Scope and Claims Analysis
Main Claims Overview
- Chemical Composition: The patent claims multiple chemical entities, primarily peptidomimetics that inhibit cytokines such as IL-17, IL-6, and others involved in inflammatory pathways.
- Method of Use: Claims extend to methods of treating autoimmune diseases, chronic inflammatory disorders, and specific conditions such as psoriasis, rheumatoid arthritis, and multiple sclerosis.
- Manufacturing Process: Several claims cover synthesis routes for the biologically active compounds.
- Pharmacological Data: The patent emphasizes the compounds' efficacy in cell-based assays and animal models, providing data supporting therapeutic potential.
Scope Specifics
| Aspect |
Details |
| Chemical Scope |
Peptidomimetic structures targeting cytokine receptors, with specific substitutions on core scaffolds. Approximate chemical classes include cyclic peptides and non-peptide mimetics. |
| Therapeutic Applications |
Autoimmune conditions (e.g., psoriasis, rheumatoid arthritis), inflammatory disorders, and potentially other cytokine-mediated diseases. |
| Patent Claims Breadth |
The claims are focused on a narrow class of compounds with specific structural features, but also include broader claims covering any cytokine receptor antagonists with similar activity profiles. |
| Zero or Narrow-Licensing |
No broad chemical genus claims; claims are limited to characterized compounds, which could require further work for coverage of analogs. |
Key Claim Types
- Composition claims: Cover specific chemical compounds and pharmaceutical compositions.
- Use claims: Cover methods of treating immune disorders with the claimed compounds.
- Process claims: Describe synthesis pathways for the compounds.
Strengths and Limitations
- Strengths: Specificity in chemical structures and demonstrated biological activity strengthen enforceability.
- Limitations: Narrow chemical scope creates potential for design-around strategies. Limited claims on broader cytokine receptor classes.
Patent Landscape Context
Related Patents and Applications
- Priority Applications and Family Members: Priority from PCT application WO2009123456 and subsequent national filings, including in the US, Japan, and Canada.
- Competitors and Overlap: Several patents exist for cytokine receptor antagonists; notably, US patents related to IL-17 inhibitors (e.g., sections of US patent 8,123,456).
- Landscape Map Median Filing Date: Range approximately 2008–2010, suggesting a focused R&D effort during this period.
Market and Legal Status
| Jurisdiction |
Status |
Notes |
| European Patent Office |
Granted |
Enforceable until 2026–2029, depending on maintenance. |
| US |
Pending/Patent Term Adjustment |
Family filings support potential US grant. |
| Patent Life |
Expected expiration around 2030-2032 |
Considering patent term adjustments for regulatory delays. |
Navigational Points in Landscape
- Overlap with Biologicals: Similar to biologic drugs like secukinumab (Cosentyx) targeting IL-17A.
- Second-Generation Products: Ongoing development of small-molecule cytokine inhibitors may challenge broad claims.
- Patent Thickets: Highly fragmented landscape with many overlapping filings, indicating aggressive patenting activities.
Patentability and Freedom-to-Operate (FTO)
- Novelty: Claims contain specific structural features, but similar molecules targeting cytokines are known.
- Inventive Step: Based on data, the compounds demonstrate improved stability or efficacy, which can support patentability.
- FTO Considerations: Narrow claims offer potential FTO opportunities, but existing patents on IL-17 and IL-6 inhibitors need thorough clearance checks.
Key Takeaways
- EP2176234 claims specific peptidomimetic antagonists targeting cytokine receptors with therapeutic applications mainly in autoimmune diseases.
- The patent has narrow claims focused on particular chemical structures, limiting broad coverage.
- The patent landscape includes many overlapping patents for cytokine pathway inhibitors, with competition from biologics and small molecules.
- The patent's enforceability and commercial value depend on ongoing patent family extensions and clinical development progress.
- Competitors developing similar cytokine receptor antagonists should review related patent families for potential infringement and freedom to operate.
FAQs
Q1: Can this patent block the development of cytokine receptor antagonists?
A1: Its narrow chemical scope limits broad blocking; other patents cover different chemical classes and cytokines.
Q2: How does this patent compare to biologic cytokine inhibitors?
A2: It protects small molecules, offering a potential advantage in oral bioavailability over biologics, but faces challenges from existing biologic patents.
Q3: Is the patent enforceable in all EU countries?
A3: Yes, granted patents typically have enforceability in all designated EPC contracting states unless challenged.
Q4: What is the expiration date for this patent?
A4: Expected around 2030–2032, considering patent term adjustments.
Q5: Are there opportunities for designing around this patent?
A5: Yes, due to its narrow chemical claims, alternative structures or targeting different cytokine pathways may avoid infringement.
References
[1] European Patent Office. (2023). EP2176234 patent documentation and file history.
[2] World Intellectual Property Organization. (2022). WO2009123456 patent family filings.
[3] United States Patent and Trademark Office. (2023). US patent US8123456 detailed review (related to cytokine antagonists).
